DUBLIN, October 3, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Breast Cancer Monoclonal Antibodies Market 2016-2020" report to their offering.
The global breast cancer monoclonal antibodies (mAbs) market to post a revenue of $13.7 billion by 2020.
The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer. The report also includes a discussion of the key vendors operating in this market.
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
Huge funds are required for a company to enter the global breast cancer mAbs market and invest in the R&D and manufacturing processes related to the same. Vendors have identified mAb products as a significant long-term growth opportunity. The pharmaceutical industry is a research-intensive industry backed by developments in technology. The vendors in this market are allocating huge R&D budgets to enable the introduction of a broad portfolio of mAbs. This would help increase the market penetration of the vendors in the global market to a great extent. Thus, the huge investment in the R&D of mAbs is another trend witnessed by the global breast cancer mAbs market, influencing market growth.
According to the report, exposure to risk factors will be a key driver for market growth. Exposure to risk factors for breast cancer and the decrease in practices that reduce this risk are expected to increase the incidence of breast cancer. The disease is associated with modifiable risk factors such as physical inactivity, alcohol consumption, obesity, and weight gain. For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.
Further, the report states that the number of patients available for clinical studies is less, making it difficult to generate significant comparative data. This is a major challenge in conducting clinical studies and for the market. The participation of sites across multiple geographies is required, but only very few patients are enrolled at each site. This may lead to delays in the recruitment process, which can add to the cost and uncertainty of the program.
Other prominent vendors
- Array BioPharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celldex Therapeutics
- Chugai Pharmaceutical
- Daiichi Sankyo
- DARA Biosciences
- Galena Biopharma
- Halozyme Therapeutics
- Puma Biotechnology
- Seattle Genetics
- Sun Pharmaceutical Industries
- Synta Pharmaceuticals
- Teva Pharmaceuticals
For more information about this report visit http://www.researchandmarkets.com/research/84jn3t/global_breast
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets